| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AAV2 and severe acute hepatitis of unknown aetiology
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
6 |
p. 493
|
artikel
|
| 2 |
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial
|
Li, Jun
|
|
|
|
6 |
p. 548-560
|
artikel
|
| 3 |
Adjuvant 131I-metuximab in hepatocellular carcinoma: a new option for an old drug?
|
Vogel, Arndt
|
|
|
|
6 |
p. 517-519
|
artikel
|
| 4 |
Affordable treatment and political commitment are crucial to eliminate hepatitis C globally
|
Hellard, Margaret
|
|
|
|
6 |
p. 414-416
|
artikel
|
| 5 |
A global perspective on oesophageal cancer: two diseases in one
|
Ho, Andrew L K
|
|
|
|
6 |
p. 521-522
|
artikel
|
| 6 |
Are postbiotics key to the potential benefits of fermented foods?
|
Gill, Paul
|
|
|
|
6 |
p. 509
|
artikel
|
| 7 |
Assessing the impact of lowering the colorectal cancer screening age to 45 years
|
Liang, Peter S
|
|
|
|
6 |
p. 523-524
|
artikel
|
| 8 |
Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial
|
Lindsay, James O
|
|
2017
|
|
6 |
p. 399-406
8 p.
|
artikel
|
| 9 |
Beyond the Milan criteria for liver transplantation in children with hepatic tumours
|
de Ville de Goyet, Jean
|
|
2017
|
|
6 |
p. 456-462
7 p.
|
artikel
|
| 10 |
Breaking the bathroom stigma on Channel 4
|
Becker, Stephanie C
|
|
|
|
6 |
p. 510
|
artikel
|
| 11 |
Broken but hopeful
|
Dorn, Aaron van
|
|
2017
|
|
6 |
p. 397-398
2 p.
|
artikel
|
| 12 |
Bullying biosimilars: cheaper drugs stymied in USA
|
The Lancet Gastroenterology & Hepatology,
|
|
2018
|
|
6 |
p. 371
|
artikel
|
| 13 |
Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial
|
Ishikawa, Hideki
|
|
|
|
6 |
p. 474-481
|
artikel
|
| 14 |
Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials
|
Geldof, Jeroen
|
|
|
|
6 |
p. 576-584
|
artikel
|
| 15 |
Claude Bernard: no ordinary man
|
Burki, Talha Khan
|
|
2018
|
|
6 |
p. 381
|
artikel
|
| 16 |
Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures
|
Roseira, Joana
|
|
|
|
6 |
p. 503
|
artikel
|
| 17 |
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist
|
Mahadevan, Uma
|
|
|
|
6 |
p. 501-502
|
artikel
|
| 18 |
Comparison of trends in early-onset colorectal cancer in North America and Europe
|
Voigtländer, Sven
|
|
|
|
6 |
p. 505-506
|
artikel
|
| 19 |
Comparison of trends in early-onset colorectal cancer in North America and Europe – Authors' reply
|
Patel, Swati G
|
|
|
|
6 |
p. 506
|
artikel
|
| 20 |
Correction to Lancet Gastroenterol Hepatol 2017; 2: 427–34
|
|
|
2017
|
|
6 |
p. e3-
1 p.
|
artikel
|
| 21 |
Correction to Lancet Gastroenterol Hepatol 2018; 4: 435–44
|
|
|
|
|
6 |
p. e5
|
artikel
|
| 22 |
Correction to Lancet Gastroenterol Hepatol 2018; 3: 337–48
|
|
|
2018
|
|
6 |
p. e3
|
artikel
|
| 23 |
Correction to Lancet Gastroenterol Hepatol 2020; 5: 430–31
|
|
|
|
|
6 |
p. e5
|
artikel
|
| 24 |
Correction to Lancet Gastroenterol Hepatol 2021; 6: 482–97
|
|
|
|
|
6 |
p. e5
|
artikel
|
| 25 |
Correction to Lancet Gastroenterol Hepatol 2022; 7: 522–32
|
|
|
|
|
6 |
p. e5
|
artikel
|
| 26 |
Correction to Lancet Gastroenterol Hepatol 2022; 7: 513–21
|
|
|
|
|
6 |
p. 508
|
artikel
|
| 27 |
Correction to Lancet Gastroenterol Hepatol 2022; 5: 426–45
|
|
|
|
|
6 |
p. 508
|
artikel
|
| 28 |
COVID-19 and the liver: little cause for concern
|
Bangash, Mansoor N
|
|
|
|
6 |
p. 529-530
|
artikel
|
| 29 |
COVID-19, childhood obesity, and NAFLD: colliding pandemics
|
Moore, J Bernadette
|
|
|
|
6 |
p. 499-501
|
artikel
|
| 30 |
COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy
|
Bhoori, Sherrie
|
|
|
|
6 |
p. 532-533
|
artikel
|
| 31 |
Delineating the global challenges of hepatitis B virus infection
|
Dusheiko, Geoffrey
|
|
2018
|
|
6 |
p. 372-373
|
artikel
|
| 32 |
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease
|
Wellens, Judith
|
|
|
|
6 |
p. 507
|
artikel
|
| 33 |
Diagnosis and treatment of Crohn's disease
|
|
|
|
|
6 |
p. 423-424
|
artikel
|
| 34 |
Diffusion-weighted MRI in inflammatory bowel disease
|
Pouillon, Lieven
|
|
2018
|
|
6 |
p. 433-443
|
artikel
|
| 35 |
Dilation after small biliary sphincterotomy
|
Gkolfakis, Paraskevas
|
|
|
|
6 |
p. 414-415
|
artikel
|
| 36 |
Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa
|
Opio, Christopher K
|
|
|
|
6 |
p. 498-499
|
artikel
|
| 37 |
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial
|
Kobayashi, Taku
|
|
|
|
6 |
p. 429-437
|
artikel
|
| 38 |
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
|
Merle, Philippe
|
|
|
|
6 |
p. 454-465
|
artikel
|
| 39 |
Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa
|
Shimakawa, Yusuke
|
|
2017
|
|
6 |
p. 393-
1 p.
|
artikel
|
| 40 |
Early age at diagnosis of hepatocellular carcinoma in sub-Saharan Africa – Authors' reply
|
Yang, Ju Dong
|
|
2017
|
|
6 |
p. 394-
1 p.
|
artikel
|
| 41 |
Effect of the COVID-19 pandemic on endoscopic surveillance in Lynch syndrome in the Netherlands
|
van Liere, Elsa L S A
|
|
|
|
6 |
p. 504-506
|
artikel
|
| 42 |
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial
|
Andrieux-Meyer, Isabelle
|
|
|
|
6 |
p. 448-458
|
artikel
|
| 43 |
Eliminating HCV: a marathon, not a sprint
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
6 |
p. 515
|
artikel
|
| 44 |
Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group
|
Shen, Bo
|
|
|
|
6 |
p. 482-497
|
artikel
|
| 45 |
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period
|
Iacucci, Marietta
|
|
|
|
6 |
p. 598-606
|
artikel
|
| 46 |
Enteric involvement in hospitalised patients with COVID-19 outside Wuhan
|
Wan, Yunle
|
|
|
|
6 |
p. 534-535
|
artikel
|
| 47 |
Enterobius vermicularis infection associated with positive faecal occult blood testing and eosinophilia
|
Lamb, Christopher A
|
|
|
|
6 |
p. 510
|
artikel
|
| 48 |
Equality, diversity, and inclusion in UK gastroenterology
|
Veitch, Andrew
|
|
|
|
6 |
p. 504
|
artikel
|
| 49 |
ESGE Days 2021
|
Brierley, Rob
|
|
|
|
6 |
p. 427
|
artikel
|
| 50 |
First-line chemotherapy plus immunotherapy in biliary tract cancer
|
Neuzillet, Cindy
|
|
|
|
6 |
p. 496-497
|
artikel
|
| 51 |
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
|
Oh, Do-Youn
|
|
|
|
6 |
p. 522-532
|
artikel
|
| 52 |
Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis
|
Li, Yunhao
|
|
|
|
6 |
p. 553-564
|
artikel
|
| 53 |
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
|
|
|
2018
|
|
6 |
p. 383-403
|
artikel
|
| 54 |
HBV elimination in sub-Saharan Africa: Rwanda's approach to health system integration
|
Makuza, Jean Damascene
|
|
|
|
6 |
p. 511-512
|
artikel
|
| 55 |
Hepatitis B virus infection in children and adolescents
|
Indolfi, Giuseppe
|
|
|
|
6 |
p. 466-476
|
artikel
|
| 56 |
Hepatitis C virus infection in children and adolescents
|
Indolfi, Giuseppe
|
|
|
|
6 |
p. 477-487
|
artikel
|
| 57 |
How can we achieve WHO's elimination target for hepatitis C incidence?
|
Øvrehus, Anne Lindebo Holm
|
|
|
|
6 |
p. 415-417
|
artikel
|
| 58 |
How do global trends in Helicobacter pylori prevalence inform prevention planning?
|
Butt, Julia
|
|
|
|
6 |
p. 498-499
|
artikel
|
| 59 |
How should we talk about alcohol and risk?
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
6 |
p. 413
|
artikel
|
| 60 |
Impairment of colorectal cancer screening during the COVID-19 pandemic
|
Semenov, Serhiy
|
|
|
|
6 |
p. 426
|
artikel
|
| 61 |
Impairment of colorectal cancer screening during the COVID-19 pandemic
|
Laghi, Luigi
|
|
|
|
6 |
p. 425-426
|
artikel
|
| 62 |
Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis
|
Artenie, Adelina
|
|
|
|
6 |
p. 533-552
|
artikel
|
| 63 |
Inflammation and malnutrition in inflammatory bowel disease
|
Massironi, Sara
|
|
|
|
6 |
p. 579-590
|
artikel
|
| 64 |
Infliximab biosimilar CT-P13 for inflammatory bowel disease
|
Bonovas, Stefanos
|
|
2018
|
|
6 |
p. 373-375
|
artikel
|
| 65 |
Infliximab discontinuation in patients with ulcerative colitis
|
Ungar, Bella
|
|
|
|
6 |
p. 412-413
|
artikel
|
| 66 |
Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver
|
Shribman, Samuel
|
|
|
|
6 |
p. 560-575
|
artikel
|
| 67 |
Irritable bowel syndrome: a spotlight on future research needs
|
Black, Christopher J
|
|
|
|
6 |
p. 419-422
|
artikel
|
| 68 |
Is there anybody out there?
|
VanHouten, Melissa Adams
|
|
2018
|
|
6 |
p. 382
|
artikel
|
| 69 |
Laparoscopic pancreatoduodenectomy: extensive learning curve, marginal benefits
|
Schneider, Martin
|
|
|
|
6 |
p. 413-414
|
artikel
|
| 70 |
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours: a multicentre, open-label, randomised controlled trial
|
Wang, Min
|
|
|
|
6 |
p. 438-447
|
artikel
|
| 71 |
Lessons in post-infectious IBS: the Walkerton tragedy
|
Mohammadi, Dara
|
|
2017
|
|
6 |
p. 396-
1 p.
|
artikel
|
| 72 |
Long-term challenges and perspectives of pre-adolescent liver disease
|
Hadžić, Nedim
|
|
2017
|
|
6 |
p. 435-445
11 p.
|
artikel
|
| 73 |
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study
|
Trauner, Michael
|
|
|
|
6 |
p. 445-453
|
artikel
|
| 74 |
Long-term outcomes with obeticholic acid in primary biliary cholangitis: reassuring, but still an itch we need to scratch
|
Eaton, John E
|
|
|
|
6 |
p. 417-418
|
artikel
|
| 75 |
Low-dose aspirin and mesalazine for patients with familial adenomatous polyposis
|
Lynch, Patrick M
|
|
|
|
6 |
p. 418-419
|
artikel
|
| 76 |
More than what meets the mouth and nose
|
Lau, Esther
|
|
2017
|
|
6 |
p. 397-
1 p.
|
artikel
|
| 77 |
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma
|
Wei, Fangqiang
|
|
|
|
6 |
p. 504
|
artikel
|
| 78 |
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma – Authors' reply
|
Marron, Thomas U
|
|
|
|
6 |
p. 505
|
artikel
|
| 79 |
Obesity: another ongoing pandemic
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
6 |
p. 411
|
artikel
|
| 80 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study
|
Petta, Salvatore
|
|
2017
|
|
6 |
p. 427-434
8 p.
|
artikel
|
| 81 |
Once-only colonoscopy or two rounds of faecal immunochemical testing 2 years apart for colorectal cancer screening (SCREESCO): preliminary report of a randomised controlled trial
|
Forsberg, Anna
|
|
|
|
6 |
p. 513-521
|
artikel
|
| 82 |
Optimal dilation time for combined small endoscopic sphincterotomy and balloon dilation for common bile duct stones: a multicentre, single-blinded, randomised controlled trial
|
Meng, Wenbo
|
|
|
|
6 |
p. 425-434
|
artikel
|
| 83 |
Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome
|
Shah, Eric D
|
|
|
|
6 |
p. 416-417
|
artikel
|
| 84 |
Outcomes of minimum unit pricing for alcohol in Scotland
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
6 |
p. 493
|
artikel
|
| 85 |
Paediatric liver disease: lessons for adult practice
|
Kelly, Deirdre A
|
|
2017
|
|
6 |
p. 390-392
3 p.
|
artikel
|
| 86 |
PARP inhibitors and chemoradiation for rectal cancer
|
Glynne-Jones, Rob
|
|
2017
|
|
6 |
p. 389-390
2 p.
|
artikel
|
| 87 |
Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China
|
An, Ping
|
|
|
|
6 |
p. 525-527
|
artikel
|
| 88 |
Prevention of SARS-CoV-2 infection in patients with decompensated cirrhosis
|
Xiao, Yong
|
|
|
|
6 |
p. 528-529
|
artikel
|
| 89 |
Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA
|
Rich, Nicole E
|
|
|
|
6 |
p. 422-424
|
artikel
|
| 90 |
Reframing self-expandable metal stents for Crohn's strictures
|
Genere, Juan Reyes
|
|
|
|
6 |
p. 503-504
|
artikel
|
| 91 |
Research in brief
|
Baker, Holly
|
|
2017
|
|
6 |
p. 395-
1 p.
|
artikel
|
| 92 |
Research in brief
|
Baker, Holly
|
|
2018
|
|
6 |
p. 380
|
artikel
|
| 93 |
Research in brief
|
Baker, Holly
|
|
|
|
6 |
p. 422
|
artikel
|
| 94 |
Research in brief
|
Baker, Holly
|
|
|
|
6 |
p. 536
|
artikel
|
| 95 |
Research in brief
|
Baker, Holly
|
|
|
|
6 |
p. 428
|
artikel
|
| 96 |
Research in Brief
|
Baker, Holly
|
|
|
|
6 |
p. 508
|
artikel
|
| 97 |
Research in Brief
|
Baker, Holly
|
|
|
|
6 |
p. 510
|
artikel
|
| 98 |
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
|
Israelsen, Mads
|
|
|
|
6 |
p. 523-532
|
artikel
|
| 99 |
Rifaximin-α in alcohol-associated liver disease
|
Xie, Chencheng
|
|
|
|
6 |
p. 495-497
|
artikel
|
| 100 |
Risk of colorectal cancer incidence and mortality after polypectomy: a Swedish record-linkage study
|
Song, Mingyang
|
|
|
|
6 |
p. 537-547
|
artikel
|
| 101 |
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial
|
Reni, Michele
|
|
2018
|
|
6 |
p. 413-423
|
artikel
|
| 102 |
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial
|
Kateera, Fredrick
|
|
|
|
6 |
p. 533-541
|
artikel
|
| 103 |
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial
|
Gupta, Neil
|
|
|
|
6 |
p. 542-551
|
artikel
|
| 104 |
Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study
|
Czito, Brian G
|
|
2017
|
|
6 |
p. 418-426
9 p.
|
artikel
|
| 105 |
San Francisco's ambitious plan to eliminate hepatitis C
|
Nelson, Roxanne
|
|
2018
|
|
6 |
p. 378
|
artikel
|
| 106 |
SARS-CoV-2 in wastewater: potential health risk, but also data source
|
Lodder, Willemijn
|
|
|
|
6 |
p. 533-534
|
artikel
|
| 107 |
Screening faecal microbiota transplant donors for SARS-CoV-2 by molecular testing of stool is the safest way forward
|
Green, Christopher A
|
|
|
|
6 |
p. 531
|
artikel
|
| 108 |
Semaglutide in NASH-related cirrhosis: too late to the party?
|
Bril, Fernando
|
|
|
|
6 |
p. 494-495
|
artikel
|
| 109 |
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
|
Loomba, Rohit
|
|
|
|
6 |
p. 511-522
|
artikel
|
| 110 |
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial
|
Strik, Anne S
|
|
2018
|
|
6 |
p. 404-412
|
artikel
|
| 111 |
Sessile serrated polyps and colorectal cancer mortality
|
Meester, Reinier G S
|
|
|
|
6 |
p. 516-517
|
artikel
|
| 112 |
Shifting the treatment model for resectable pancreatic cancer
|
Ko, Andrew H
|
|
2018
|
|
6 |
p. 375-376
|
artikel
|
| 113 |
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination
|
Meyer, Tim
|
|
2018
|
|
6 |
p. 376-377
|
artikel
|
| 114 |
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial
|
Kudo, Masatoshi
|
|
2018
|
|
6 |
p. 424-432
|
artikel
|
| 115 |
Status of HBV birth dose vaccination in Africa: the impact of COVID-19 and Gavi support on policy development
|
Njuguna, Henry N
|
|
|
|
6 |
p. 502-503
|
artikel
|
| 116 |
Stem-cell transplantation for Crohn's disease: same authors, different conclusions?
|
Burt, Richard K
|
|
2017
|
|
6 |
p. 386-387
2 p.
|
artikel
|
| 117 |
Stigma and irritable bowel syndrome: a taboo subject?
|
Hearn, Mark
|
|
|
|
6 |
p. 607-615
|
artikel
|
| 118 |
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial
|
Kudo, Masatoshi
|
|
2017
|
|
6 |
p. 407-417
11 p.
|
artikel
|
| 119 |
Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen up
|
Sanduzzi-Zamparelli, Marco
|
|
|
|
6 |
p. 418-420
|
artikel
|
| 120 |
The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study
|
Trickey, Adam
|
|
|
|
6 |
p. 435-444
|
artikel
|
| 121 |
The effect of sleep on gastrointestinal functioning in common digestive diseases
|
Orr, William C
|
|
|
|
6 |
p. 616-624
|
artikel
|
| 122 |
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas
|
Díaz, Luis Antonio
|
|
|
|
6 |
p. 552-559
|
artikel
|
| 123 |
The global burden of gastro-oesophageal reflux disease: more than just heartburn and regurgitation
|
Sweis, Rami
|
|
|
|
6 |
p. 519-521
|
artikel
|
| 124 |
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|
|
|
|
|
6 |
p. 561-581
|
artikel
|
| 125 |
The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
|
|
|
|
|
6 |
p. 582-597
|
artikel
|
| 126 |
The International Liver Congress 2018
|
Brierley, Rob
|
|
2018
|
|
6 |
p. 379
|
artikel
|
| 127 |
The International Liver Congress 2019
|
Brierley, Rob
|
|
|
|
6 |
p. 421
|
artikel
|
| 128 |
The intersection between eating disorders and gastrointestinal disorders: a narrative review and practical guide
|
Staller, Kyle
|
|
|
|
6 |
p. 565-578
|
artikel
|
| 129 |
The intestinal microbiome and paediatric liver disease
|
Leung, Daniel H
|
|
2017
|
|
6 |
p. 446-455
10 p.
|
artikel
|
| 130 |
The opioid crisis: the needle and the damage done
|
The Lancet Gastroenterology & Hepatology,
|
|
2017
|
|
6 |
p. 385-
1 p.
|
artikel
|
| 131 |
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis
|
Bosman, Michelle
|
|
|
|
6 |
p. 459-473
|
artikel
|
| 132 |
The problem of antimicrobial resistance in chronic liver disease
|
The Lancet Gastroenterology & Hepatology,
|
|
|
|
6 |
p. 495
|
artikel
|
| 133 |
The relationship between gastrointestinal cancers and the microbiota
|
LaCourse, Kaitlyn D
|
|
|
|
6 |
p. 498-509
|
artikel
|
| 134 |
The road to HIV and HCV elimination among people who inject drugs
|
Corona-Mata, Diana
|
|
|
|
6 |
p. 497-498
|
artikel
|
| 135 |
The role (if any) of chemotherapy in hepatocellular carcinoma
|
El Dika, Imane
|
|
2017
|
|
6 |
p. 387-389
3 p.
|
artikel
|
| 136 |
Top 10 research priorities for irritable bowel syndrome: results of a James Lind Alliance priority setting partnership
|
Black, Christopher J
|
|
|
|
6 |
p. 499-501
|
artikel
|
| 137 |
Ulcerative pyoderma gangrenosum in inflammatory bowel disease
|
Motta, Ilaria
|
|
|
|
6 |
p. 488
|
artikel
|
| 138 |
US FDA recommends transition to disposable duodenoscopes
|
Burki, Talha
|
|
|
|
6 |
p. 509
|
artikel
|
| 139 |
US Government plans overhaul of organ transplantation system
|
Furlow, Bryant
|
|
|
|
6 |
p. 507
|
artikel
|
| 140 |
Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
|
Zingone, Fabiana
|
|
|
|
6 |
p. 525
|
artikel
|
| 141 |
When gluten attacks
|
Sargent, Jennifer
|
|
2017
|
|
6 |
p. 398-
1 p.
|
artikel
|
| 142 |
White oesophagus
|
Blouhos, Konstantinos
|
|
2018
|
|
6 |
p. 444
|
artikel
|
Tijdschrift beschrijving